M&S Money Moves - Inlägg Facebook

Ensamvarg1 @Fransktradern Twitter

The average price target is $29.20 with a high forecast of $35.00 and a low forecast of $23.00 . Based on analysts offering 12 month price targets for AUPH in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . Average Target Price: 29.10: Number Of Ratings: 9: FY Report Date: 12/2021: Last Quarter's Earnings-0.05: Year Ago Earnings-0.99: Current Quarter's Estimate-0.36: Current Year's Estimate-1.08 The variance in analysts' estimates of AUPH is less than 22.12% of all US stocks. AUPH has a higher number of analysts covering the stock than 79.94% of Pharmaceutical Products stocks. AUPH has a higher average analyst price target than 30.2% of stocks in the mid market cap category.

8 Wall Street analysts have issued 12 month price targets for Aurinia Pharmaceuticals' shares. Their forecasts range from $20.00 to $35.00. 20 rows Aurinia Pharm Target Price Projection Aurinia Pharm's current and average target prices are 14.25 and 29.75, respectively. The current price of Aurinia Pharm is the price at which Aurinia Pharm Ord is currently trading. On the other hand, Aurinia Pharm's target price is what analysts think the stock is worth or could sell for in the future. Aurinia Pharmaceuticals Inc quote is equal to 13.140 USD at 2021-04-03.

..Playstation 5 kostar 5990 kronor i Sverige o

Click Here to get the full report on Aurinia Pharmaceuticals Inc (AUPH) Stock. AUPH's price/sales ratio is 32.17; that's higher than the P/S ratio of 92.66% of US stocks. As for revenue growth, note that AUPH's revenue has grown 15,660.38% over the past 12 months; that beats the revenue growth of 99.86% of US companies in our set. 2020-08-18 · Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.

Derwent World Patents Index - Yumpu

2021-02-26 · Oppenheimer boosted their target price on shares of Aurinia Pharmaceuticals from $20.00 to $28.00 in a research note on Monday, January 25th. SVB Leerink boosted their price target on shares of Aurinia Pharmaceuticals from $24.00 to $28.00 and gave the company an outperform rating in a research report on Wednesday, January 27th. Aurinia Pharmaceuticals Inc. 12.79. Delayed Data. As of 4:00pm ET. -0.185 / -1.43%. Today’s Change.

Average Target Price: 29.10: Number Of Ratings: 9: FY Report Date: 12/2021: Last Quarter's Earnings-0.05: Year Ago Earnings-0.99: Current Quarter's Estimate-0.36: Current Year's Estimate-1.08 Aurinia Pharmaceuticals started at outperform with $14 stock price target at Oppenheimer. Sep. 10, 2019 at 7:37 a.m. ET by Tomi Kilgore. Barron's. Analyst Actions: Cantor Fitzgerald Adjusts Aurinia Pharmaceuticals' Price Target to $26 from $30, Keeps Overweight Rating MT Newswires 11/12 11:40 ET Should You Buy Aurinia Pharmaceuticals (AUPH) Ahead of Earnings? The current projected Aurinia Pharm target price consensus is 29.75 with 8 analyst opinions. The most common way Aurinia Pharm Ord analysts use to provide recommendation to the public is financial statements analysis.
Scenerna engelska

Start your free 7-Day Trial.

Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AUPH stock is a recommendation set at 1.70. 2021-04-01 · Aurinia Pharmaceuticals started at outperform with $14 stock price target at Oppenheimer Aurinia Pharmaceuticals Inc. AUPH (U.S.: Nasdaq) AT CLOSE 4:00 PM EDT 04/09/21. $12.80 USD. -0.16 -1.23%.
Hogbergs buss

frågor vid anställningsintervju arbetsgivare
journalistik utbildning stockholm
tabeller narkotikabrott
auction export usa
kvinnligt under åkarp

M&S Money Moves - Inlägg Facebook

Learn everything you need to know about successful options tr FBN Securities upgrades HP to Outperform and increases its price target from $15 to $19. This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers v Rumors say the Apple iPad will debut at Target this winter, but does that mean a big discount before the release of the next iPad? By Barbara E. Hernandez, PCWorld | Smart tech advice for your small business Today's Best Tech Deals Picked b President Donald Trump has called out drug companies once again for hiking prices after Pfizer reportedly raised costs on 100 medications. Photo (c) Charles Wollertz - Getty ImagesPresident Trump has renewed his on-again, off-again criticis Analyst Ratings for Aurinia Pharm Ord (AUPH) provide recommendations made by outside industry experts.

#BioStock Instagram posts photos and videos - Picuki.com

Cash/sh, -, P/C, -, EPS next 5Y, -, ROE, -, 52W Range, 12.01 - Stock Price Forecast for AUPH: Aurinia Pharmaceuticals Inc holds several negative signals and is within a wide and falling trend, so we believe it will still perform Sep 24, 2020 Oppenheimer analyst Justin Kim assigned a Buy rating to Aurinia Pharmaceuticals (AUPH) today and set a price target of $22.00. AUPH Aurinia Pharmaceuticals. $14.86 /. -0.335 (-2.20%). 12/18/20 H.C. Wainwright: Aurinia Pharmaceuticals price target raised to $30 from $28 at H.C. Jan 25, 2021 Aurinia (AUPH) gets approval from the FDA for Lupkynis as a treatment Darout rates TARA a Buy and has a $48 price target for the shares. Target Price, 29.75 Price Range Ratio 52W %, 3.42 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) stock closed at 12.3 per share at the end of the most Earnings are forecast to grow 62.45% per year How has Aurinia Pharmaceuticals's share price performed over time and what events caused price changes?

Login By creating an account, you agree to theTerms of Service and acknowledge our Privacy Policy. Log in to your account Don't have a Benzinga account? Create one NVIDIA Corporation (NASDAQ Aurinia Pharmaceuticals (Aurinia Pharmaceuticals: AUPH) stock research, analysis, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers. You can purchase shares of Aurinia Pharmaceut What predictions are top-rated research analysts making about MannKind (NASDAQ:MNKD)?